In this episode of #CEOInterview, we are pleased to invite Aytu BioPharma’s CEO, Josh Disbrow, to provide a corporate overview. Aytu BioPharma (Nasdaq: AYTU) is a commercial-stage pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve patients’ quality of life. Aytu is committed to enhancing the lives of individuals affected by psychiatric conditions with the company’s innovative treatments for major depressive disorder and attention deficit/hyperactivity disorder, and ensuring broad access for patients.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company’s prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company’s medications through best-in-class patient access programs that help to enable optimal patient outcomes.
For more information, please visit their website.
CEO Interview series is a program where we invite CEOs or senior executives of public companies with great growth potential. We will present investing ideas across different sectors, which helps investors to gain quicker and easier access to the most recent developments of these companies.
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.
